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Abstract
Background: Salvia miltiorrhiza (SM) has long been used as a traditional oriental medicine for cardiovascular
disease. Accumulating evidence also indicates that SM has anti-osteoporotic effects. This study was conducted to
examine the SM-induced anti-osteoporotic effect and its possible mechanisms with various doses of SM.
Methods: We studied Sprague-Dawley female rats aged 12 weeks, divided into six groups: sham-operated control
(SHAM), OVX rats supplemented with SM (1, 3, 10 and 30 mg/kg) orally for 8 weeks. At the end of the experiment,
blood samples were collected and biochemistry analysis was performed. Specimens from both tibia and liver were
processed for light microscopic examination. DEXA and μ-CT analyses of the tibia were also performed.
Results: SM treatment significantly ameliorated the decrease in BMD and trabecular bone mass according to DEXA
and trabecular bone architecture analysis of trabecular bone structural parameters by μ-CT scanning. In serum
biochemical analysis, SM decreased the released TRAP-5b, an osteoclast activation marker and oxidative stress
parameters including MDA and NO induced by OVX.
Conclusions: The preventive effect of SM was presumably due to its anti-oxidative stress partly via modulation of
osteoclast maturation and number. In current study, SM appears to be a promising osteoporosis therapeutic
natural product.
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Backgrounds
Osteoporosis is a multifactorial skeletal disease that is
characterized by compromised bone strength predispos-
ing a person to an increased risk of fracture [1]. Long-
term administration of currently prevalent medications
may lead to an increased risk of severe side effects like
cancer [2]. Salvia miltiorrhiza (SM) has long been used
as a traditional oriental medicine for cardiovascular dis-
ease. Accumulating evidence also indicates that SM has
anti-osteoporotic effects. The dried root of Salvia mil-
tiorrhiza Bunge (Labiatae) is also named Danshen or
Tanshen. The herb is mainly produced in Anhui,
Shanxi, Hebei, Shuan, and Jiangsu provinces in China
[3]. Among the chemical constituents of Danshen, there
are tanshinone I, tanshinone IIA, tanshinone IIB, crypto-
tanshinone, tanshindiol C, 15,16-dihydrotanshinone I,
isotanshinone I, isotanshinone II and other tanshinones
[4]. Several biological activities have been detected for
the major tanshinones through in vivo and/or in vitro
tests, such as antioxidant, anti-inflammatory, antimicro-
bial, anti-menopausal syndrome, anti-ischemic, and anti-
neoplastic activities [3,5,6]. The inhibitory effect of
tanshinone IIA on osteoclast differentiation and bone
resorption was also observed [7]. Consistently, SM sig-
nificantly increases the blood estrogen level in ovariecto-
mized (OVX) rats, suggesting that SM might help
prevent bone resorption in this osteoporosis model
[7,8]. These results were also related with a study sug-
gesting that SM has a positive effect on promoting
angiogenesis [9]. Wong et al. also showed that SM
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actions of increasing angiogenesis, increasing osteoblas-
tic activity and decreasing osteoclastic activity [10,11].
Our previous study revealed that aqueous extract of SM
effectively prevents the development of bone loss
induced by OVX in rats [12]. However, a detailed char-
acterization of the effect of SM has not been elucidated
yet.
T h ea i mo ft h ec u r r e n ts t u d yi st oc l a r i f yt h ea n t i -
osteoporotic effect of SM at various doses. This study
was performed in OVX rats by observing the changes in
biochemistry data, bone mineral density (BMD), trabe-
cular bone structural morphometric traits and histologi-
cal characteristics.
Methods
Materials
The dried root slices of SM were acquired from Hansol
Oriental Medical (Gimje, Korea). 1800 g of SM powder
were prepared from dried root slices of SM that were
cut into small pieces and extracted with 100% ethanol at
78°C for 3 hr in triplicate. The extract was filtered, eva-
porated on a rotary vacuum evaporator at 50°C and
freeze-dried to yield 26.52 g of SM extract. 106.56 μgo f
tanshinone IIA/10 mg of SM extracts (1.07%) and
109.655 μg of crytotanshinone/10 mg of SM extracts
(1.10%) was verified by high performance liquid chroma-
tography (HPLC).
The chemical products used in the experiment
include: methanol and acetic acid of HPLC grade
(Merck, Germany). Tanshinone IIA and cryptotanshi-
none standards were purchased from Sigma Company
(USA). Rompun (1 ml of Rompun contains 23.32 mg of
Xylazine hydrochloride) was purchased from Bayer
Korea (Ansan, Korea) and Ketamine was acquired from
Yuhan (Seoul, Korea). Estradiol Depot was obtained
from Jenapharm (KG, Germany).
Experimental Animals
Twelve-week-old female Sprague-Dawley rats, weighing
230-270 g, were purchased from Damul Science Co
(Daejeon, Korea), allowed to acclimate for 7 days, and
kept another 7 days for a baseline period before the
start of the experiment. The rats were maintained at a
constant temperature (25 ± 2°C) and humidity (55% ±
5%), with a cycle of 12 hours light and 12 hours dark-
ness. They were housed individually in standard cages
a n dw e r ep r o v i d e dw i t had libitum tap water and a
commercial standard diet containing 1.2% calcium and
0.8% phosphorus. All procedures using animals were
carried out in accordance with the guidelines presented
in the “Principles for the Care and Use of Animals in
the Field of Physiological Sciences”,p u b l i s h e db yt h e
Physiological Society of Korea. The study protocol was
approved by an ethics committee in Chonbuk National
University (Jeonju, Korea). Experiment animals were
allocated to sham-operated (Sham), OVX-control
(OVX), and 1, 3, 10 and 30 mg/kg SM treated (1SM,
3SM, 10SM and 30SM) ovariectomized groups for a
total of 6 groups (N = 10/each group). Rats in the
sham-operated group underwent a sham operation, i.e.,
only the skin incision was made. Briefly, the operations
were performed by exteriorizing the ovaries after the
baseline period at week 0; the other rats were ovariecto-
mized. Rats were operated on while under anesthesia by
a mixture of Ketamine (35 mg/kg) and Xylazine (10 mg/
kg) administrated intraperitoneally. Success of OVX was
confirmed at necropsy by retrospectively inspecting
atrophy of the uterine horns [13,14]. After a 1-week
healing period, rats in the drug-treated ovariectomized
groups were orally treated with a series dosage of SM
once daily for 8 weeks and Sham and OVX groups were
orally treated with volume-matched vehicles before sam-
pling. The doses and durations of SM treatment were
predetermined on the basis of preliminary studies [15].
The body weight of each rat was measured weekly, and
the dosage of drug or vehicle administered was calcu-
lated based on the most recent body weight measure-
ment. After 8 weeks of drug administration, the
experimental rats were fasted overnight; the next morn-
ing, rats were anesthetized and blood was sampled from
the abdominal aorta. Serum was isolated from the blood
samples by centrifugation at 3000 × g, 4°C, for 5 min
and stored at -70°C prior to biochemical measurement.
After the blood sample was collected, the rats were bled
to death, and the liver and tibiae were excised. The liver
and left tibia (defleshed) of each animal were fixed with
fixative and used for further histomorphometric analysis,
while the right tibia was freed of all soft tissue and
wrapped in a layer of PARAFILM (Menasha co., U.S.A),
apart from 5 mm of its proximal end, and fixed into a
15 ml BD Falcon Tube (BD Co., Franklin Lakes, NJ
USA) and then soaked in fixative. The tube cap was
tightened before performing a μ-CT scan to measure
the microstructural parameters. The right femurs were
subjected to DEXA measurement for BMD and bone
mineral content (BMC).
Bone μ-CT Scanning
To assess bone loss, rats right tibiae (defleshed) were ex
vivo scanned at the end of drug treatment. A 6-mm μ-
CT scan (70 kV, 85 lA, 1,000 projections per 180
degrees, 350 ms integration time) with an isotropic reso-
lution of 18 μm was made of the proximal tibia using an
in vivo μ-CT scanner (SkyScan-1076 in vivo CT-scanner;
SkyScan, Belgium) The CT scanner was calibrated, and
a beam hardening correction algorithm was applied to
all scans. One CT scan took 35 minutes. In this study,
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with a coefficient of variation of about 1%.
From the stack of cross-se c t i o ni m a g e s ,av o l u m eo f
interest (VOI) containing only cancellous bone was
extracted for morphometric analysis (CT Analyzer V
1.11.0.0, Skyscan, Kontich, Belgium). The VOI started at
ad i s t a n c eo f1m mf r o mt h el o w e re n do ft h eg r o w t h
plate and extended distally for 110 cross sections (2 mm
in height). For morphometric analysis, the following
structural parameters were calculated over each VOI of
cancellous bone by “3D analysis” (using CT Analyzer
software): bone volume fraction (BV/TV), connectivity
density (Conn.D), trabecular thickness (Tb.Th), direct
trabecular separation (Tb.Sp), trabecular number (Tb.N),
trabecular pattern factor (Tb.Pf), BMD, and structure
model index (SMI). SMI indicates whether the trabecu-
lae are more rod-like (SMI = 3) or more plate-like (SMI
= 0); Lower Tb.Pf signifies better connected trabecular
lattices while higher Tb.Pf means a more disconnected
trabecular structure; Conn.D was obtained by calculating
the connectivity of the trabecular network and normal-
i z e db yd i v i d i n gt h ec o n n e c t i v i t yb yb o n ev o l u m e( B V /
TV) [14].
The cortical area of the diaphyseal region of the tibia
was also calculated using CT Analyzer software. The cut
level for measurement of the cortical area was defined
at a distance of 8 mm from the lower end of the growth
plate. The cortical area (Ct.Ar), and cortical thickness
(Ct.Th) were analyzed by “Individual 2D object analysis”
in CT Analyzer software, and cortical thickness was cal-
culated by the formula Ct.Th = 1/2 × BS/BV. The above
formula is defined as: area of a ring = thickness of ring
× length of middle line = thickness × (outer circumfer-
ence + inner circumference)/2 [14].
The average attenuation coefficient of the trabecular
bone tissue was determined for all measurements using
a protocol provided by the manufacturer of the μ-CT
scanner. With this protocol, the gray levels of voxels
near the trabecular surfaces are not included to ensure
that the measurements are not affected by partial
volume effects.
DEXA Measurement
All DEXA measurements were performed by the same
investigator (Y. C) using the Norland pDEXA Sabre
(Fort Atkinson, WI, USA) equipped with Sabre Research
software (v3.6). The interassay coefficient of variation
(CV) for BMD and BMC was 1.7%. The scanner was
calibrated daily to a dual-material standard according to
the manufacturer’s recommendations, and the scanner
performance was controlled by the quality assurance
protocol of our laboratory. The right femurs were
scanned using DEXA to determine BMC and BMD. Ex
vivo measurements of the right distal femur were
performed on excised bones positioned onto a 3-mm-
thick cotton piece on the bottom (thickness 1 mm) of a
10-cm diameter culture dish at a constant location on
the scan table, and measured by DEXA using a special
collimator (0.8 mm diameter); the scan length was 5 cm,
the scan width 2 cm and the scan speed 10 mm/s with a
resolution of 0.2 mm × 0.2 mm [16-18]. The deltoid
tuberosity was faced upward to avoid an irregular pro-
jecting shape; the starting point of the scan was above
the distal condyle of the femur and the end point was
proximal to the femoral end so that the scanner arm
moved along the long axis of the femoral shaft allowing
evaluation of femur length. The baseline point was
located on the cotton piece [16,19].
Liver Histological Examination
Liver specimens were fixed in 10% buffered neutral par-
aformaldehyde solution, processed and embedded in
paraffin. Thin paraffin sections (5-μmt h i c k )w e r e
stained by hematoxylin and eosin (H & E). The numbers
of mononuclear cells were determined/10 HPF.
Bone Histomorphometric Analysis
Left tibiae were decalcified in 5% formic acid (in dis-
tilled water) solution for 1 week, dehydrated with
methanol, and embedded in paraffin. The paraffin sec-
tions were deparaffinized and stained (H & E). Sections
with the widest marrow cavity near the growth plate of
the metaphysis of tibiae were selected for further histo-
logical processing and histomorphometric
measurements.
Histomorphometrical measurements were made using
an Optiphot 2 microscope connected to a RGB camera
and a personal computer (software: Lucia G 4.51,
Laboratory Imaging), with final magnifications of 30×
and 400×. The number of osteoclasts (Oc.N) was deter-
mined/10 HPF.
BALP Enzyme Assay
Rat bone alkaline phosphatase (BALP) enzyme-linked
immunosorbent assay (ELISA) kit was provided by
Cusabio Biotech Co., LTD. (Wuhan, China). Rat BALP
w a sa l s om e a s u r e du s i n gE L I S Af r o mR&DS y s t e m s
(Minneapolis, MN, USA).
TRAP Enzyme Assay
Rat TRAP-5b EIA Kit was obtained from KAMIYA
BIOMEDICAL Company (Seattle, WA, USA). Rat
TRAP-5b was also measured by ELISA (R & D Systems,
Minneapolis, MN, USA).
Plasma Peroxide Assay
The plasma malondialdehyde (MDA) levels were deter-
mined according to the method of Draper and Hadley
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bituric acid. Measurement was conducted using the lipid
peroxidation assay kit (Calbiochem). The absorbance at
586 nm was measured using an ELISA microplate
reader.
Plasma Nitrate Assay
Plasma nitrate levels were measured according to the
method of Bories and Bories (1995) [21]. Total serum
nitric oxide (NO) was calculated based on the enzymatic
conversion of nitrate to nitrite by nitrate reductase,
using a commercial kit (Total Nitric Oxide and Nitrate/
Nitrite Parameter Assay Kit, R&D SYSTEMS, Minnea-
polis, MN, USA).
Biochemical Analysis of Serum Parameters
Serum content of calcium, inorganic phosphorus (IP),
ALP, triiodothyronine (T3), thyroxine (T4), osteocalcin,
estradiol, intact PHT and calcitonin were determined
using standard laboratory techniques. Serum levels of
free T4,f r e eT 3, intact PTH, and estradiol were mea-
sured with free T3,f r e eT 4, Elecys PTH, and Estradiol a
kits (Roche, Germany), respectively, using Modular Ana-
lytics E170 (Roche, Germany) in the electrochemilumi-
nescence immunoassay method. Serum calcium and IP
were measured with related kits (Roche, Germany) using
Modular Analytics PE (Roche, Germany) in the colori-
metric and phosphomolybdate & ultraviolet spectropho-
tometric methods, respectively. Serum ALP activity was
measured with ALP kit (Roche, Germany) using Modu-
lar Analytics PE (Roche, Germany) with colorimetry
with PNPP. Calcitonin was measured with Liaison calci-
tonin a-Gen kit (Diasorin, USA) by the chemilumines-
cent immunoassay method.
Statistical Analysis
Data are expressed as means ± SD. Statistical signifi-
cance for data was determined using one-way analysis of
variance (ANOVA) with post-hoc test, and significance
was calculated by LSD (least significant difference) mul-
tiple range-test to find inter-group significance. The
level of significance was accepted as p< 0.05.
Results
Preparation of SM extracts
In the pure components of SM, tanshinone I, tanshi-
none IIA, tanshinone IIB, cryptotanshinone, tanshindiol
C, 15,16-dihydrotanshinone I, isotanshinone I, isotanshi-
none II and other tanshinones are included [4]. Among
the tanshinone compounds, tanshinone IIA and crypto-
tanshinone were selected as active and quality control
compounds in this study. Calibration curves of the two
compounds were constructed by measuring different
concentrations. Good linearity was observed for
tanshinone IIA (r
2 = 0.9911) and cryptotanshinone (r
2 =
0.9921). The regression equations for t`anshinone IIA
and cryptotanshinone were y = 59467x + 296829 and y
= 62354x - 109248, respectively (data not shown). The
typical HPLC-UV profiles are illustrated in Additional
file 1. The HPLC condition has been also described in
Additional file 2. Good separation was achieved within
25 min. The retention times for cryptotanshinone and
Tanshinone IIA were 14.8 and 21.6 min. The content of
tanshinone IIA and cryptotanshinone in Salvia Miltior-
rhiza was determined from the corresponding regression
equation. Tanshinone IIA content was 106.56 μg/10 mg
of SM extract (1.07%) whereas cryptotanshinone content
was 109.655 μg/10 mg of SM extract (1.10%).
Body Weight Changes
As time passed from 2 to 8 weeks after OVX, the aver-
age body weight growth in the OVX groups was signifi-
cantly greater than that in the Sham group (p <
0.05~0.001), but administration of SM did not affect the
body weight growth pattern (Additional file 3).
BMD and BMC
In DEXA ex vivo measurement, the aBMD and aBMC of
right distal femora were significantly decreased by 38%,
respectively, by OVX (p < 0.001). SM administration
provided some degree of safety in a dose-dependent
manner, but only high-dosage SM (30 mg/kg body
weight/day) treatment significantly prevented aBMD and
aBMC reduction by 33%, respectively (p < 0.05) (Figure
1A, B). In μ-CT ex vivo measurement, the vBMD of
proximal tibiae was significantly reduced by 74% (p <
0.001), and SM treatment resulted in the same pattern
as in DEXA measurement, i.e., the vBMD decrease was
prevented by 22% only in 30SM rats (p < 0.05) (Figure
1C). This study showed the coronal images of rat med-
ial-proximal tibia by μ-CT (Figure 2A) and 3D images
μ-CT (Figure 2B) with the taken by SM dose-dependent
prevention about bone loss in OVX rats.
μ-CT Evaluation
To examine the effect of SM on BMD, coronal image of
proximal-medial tibia was taken ex vivo by μ-CT. A.
Additional file 4 showed setting conditions for the μ-
CT. Table 1 showed that OVX induced significant
changes in all trabecular microstructural parameters in
the proximal tibial metaphysis measured by μ-CT. Com-
pared with Sham rats, OVX significantly reduced bone
volume fraction (BV/TV), by 87% (p < 0.001), trabecular
thickness (Tb.Th) by 14% (p < 0.001), trabecular num-
ber (Tb.N) by 85% (p < 0.001) and connectivity density
(Conn.D) by 91% (p < 0.001), and increased trabecular
separation (Tb.Sp) by 320% (p <0 . 0 0 1 ) .O t h e rm i c r o -
structural parameters such as SMI and trabecular bone
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0.001). SM treatment also showed some tendency for
dose-dependent safety effects but only the maximum
SM treatment of 30 mg/kg had a significant preventive
effect, attenuating reduction of BV/TV by 24% (p <
0.05), Tb.Th by 65% (p < 0.05), Tb.N by 23% (p <0 . 0 5 )
and Conn.D by 12% (p <0 . 0 5 ) ,w h i l ep r e v e n t i n g
increase of Tb.Sp by 43% (p < 0.05), SMI by 30% (p <
0.05) and Tb.Pf by 28% (p < 0.05). Ct. Ar and Ct. Th
measured by μ-CT were also summarized in the Table
1. OVX did not affect the cortical area and thickness of
tibial diaphysis.
Bone Histomorphometric Parameters
As shown in Table 2 and Figure 3, the histomorpho-
metric parameters were analogous to the μ-CT observa-
tions of trabecular morphology: OVX significantly
reduced BV/TV by 82% (p < 0.001), Tb.Th by 58% (p <
0.001), Tb.N by 64% (p < 0.001), and increased Tb.Sp by
604% (p < 0.001). SM treatment also tended to have a
dose-dependent preventive effect at the experimental
dosages, but only treatment with the maximum of 30
mg/kg body weight/kg of SM showed significance,
attenuating reduction of BV/TV by 19% (p <0 . 0 5 ) ,T b .
Th by 57% (p < 0.05), and Tb.N by 65% (p <0 . 0 5 ) ,
w h i l ep r e v e n t i n gt h ei n c r e a s eo fT b . S pb y6 9 %( p <
0.05). OVX also induced a significant increase in Oc.N
(p < 0.001 vs. Sham), and SM treatment attenuated the
Oc.N increase only in the 30SM group (p <0 . 0 5v s .
OVX).
Liver Histomorphometry
As shown in Figure 4 and Table 3, OVX aggravated
mononuclear cellular infiltration in the portal area of
the liver (p < 0.001 vs. Sham rats) and SM treatment
significantly ameliorated mononuclear cellular infiltra-
tion only at 30 mg/kg body weight/day (p <0 . 0 5v s .
OVX rats).
Quantification of Serum bone turnover markers
A ss h o w ni nF i g u r e5 A ,s e r u mB A L Pa sab o n ef o r m a -
tion marker [22] was significantly increased in OVX rats
(p < 0.05), while drug treatment did not affect the
increase.
TRAP 5b in serum is proposed to be a marker for
osteoclasts [23]. As shown in Figure 5B, serum TRAP
5b was significantly increased in OVX rats compared
with Sham group (p < 0.05) but was significantly attenu-
ated in 30SM group (p < 0.05), consistent with exchange
in osteoclast number measured by histological assess-
ment (Table 2) and indicating increased bone resorp-
tion. In order to understand the mechanism of SM on
bone resportion parameter, malondialdehyde (MDA)
Figure 1 The Quantification of BMD and BMC in SM-treated
rats. aBMD (A) and aBMC (B) of right distal femur ex vivo measured
by DEXA, and vBMD (C) of right proximal tibia ex vivo measured μ-
CT. OVX significantly decreased aBMD,by aBMC and vBMD,
respectively. Although SM treatment tended to have a dose-
dependent preventive effect, only treatment with 30 mg/kg body
weight/day of SM significantly prevented BMD and BMC decrease
induced by OVX. Note: *p < 0.001 vs Sham group;
#p < 0.05 vs OVX
group
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Page 5 of 11Table 1 Trabecular microstructural properties of the right tibial metaphysis and cortical geometric properties
evaluated ex vivo using micro-CT.
Parameters Sham
n=1 0
OVX
n=1 0
SM1
n=7
SM3
n=8
SM10
n=1 0
SM30
n=9
BV/TV (%) 30.06 ± 4.57 3.90 ± 1.61 * 4.56 ± 2.44 * 4.92 ± 1.84 * 6.22 ± 1.78 * 8.05 ± 3.32 *,
#
Tb.Th (μm) 112.76 ± 7.95 96.51 ± 4.99 * 101.03 ± 6.58 * 100.06 ± 7.42 * 99.53 ± 5.92 * 107.03 ± 5.02 *,
#
Tb.N (1/mm) 2.67 ± 0.40 0.40 ± 0.16 * 0.45 ± 0.23 * 0.50 ± 0.19 * 0.63 ± 0.19 * 0.93 ± 0.28 *,
#
Tb.Sp (mm) 0.25 ± 0.08 1.05 ± 0.13 * 1.05 ± 0.26 * 1.03 ± 0.20 * 0.93 ± 0.21 * 0.71 ± 0.10 *,
#
Conn.D (1/mm
3) 97.53 ± 12.90 8.95 ± 3.67 * 9.24 ± 4.90 * 10.59 ± 3.22 * 14.24 ± 6.62 * 19.37 ± 6.34 *,
#
Tb.Pf (1/mm) 4.25 ± 2.29 20.35 ± 2.98 * 19.50 ± 2.26 * 18.98 ± 1.89 * 18.48 ± 2.62 * 15.79 ± 3.05 *,
#
SMI (1) 1.46 ± 0.25 2.69 ± 0.10 * 2.64 ± 0.12 * 2.61 ± 0.14 * 2.59 ± 0.16 * 2.32 ± 0.26 *,
#
Ct.Ar (mm
2) 5.38 ± 0.22 5.41 ± 0.45 5.98 ± 0.34 5.67 ± 0.43 5.58 ± 0.34 5.29 ± 0.31
Ct.Th (mm) 29.65 ± 0.13 29.63 ± 0.09 29.65 ± 0.07 29.54 ± 0.10 29.62 ± 0.06 29.66 ± 0.08
Note: Results are presented as the means ± SD. *p < 0.001 vs. Sham group;
#p < 0.05 vs. OVX group. BV/TV, bone volume fraction; Conn.D, connectivity density;
SMI, structure model index; Tb.Th, trabecular thickness; Tb.N, trabecular number; Tb.Sp, trabecular separation; Tb.Pf, Trabecular bone pattern factor; Ct.Ar, cortical
area; Ct.Th, cortical thickness. Rat groups include sham-operated (Sham), OVX-control (OVX), and 1, 3, 10 and 30 mg/kg SM treated (1SM, 3SM, 10SM AND 30SM)
ovariectomized groups for a total of 6 groups (N = 7~10/each group).
Table 2 Histomorphometric parameters of trabecular bone from metaphysis of tibiae evaluated by histochemical
analysis.
Parameters Sham
n=7
OVX
n=7
1SM
n=7
3SM
n=7
10SM
n=7
30SM
n=7
BV/TV (%) 55.44 ± 7.10 10.24 ± 3.68 * 11.51 ± 2.27 11.61 ± 2.27 15.19 ± 1.61 18.70 ± 1.38
#
Tb.Th (mcm) 35.14 ± 5.17 14.86 ± 5.54 * 15.72 ± 3.33 16.37 ± 3.03 21.32 ± 3.71 26.37 ± 2.49
#
Tb.N (1/mm) 15.87 ± 1.59 5.73 ± 2.03 * 6.06 ± 1.99 6.39 ± 2.00 8.88 ± 2.61 12.35 ± 2.67
#
Tb.Sp (mcm) 28.38 ± 5.80 199.70 ± 3.48 * 180.27 ± 3.46 176.26 ± 2.18 98.75 ± 7.21 81.67 ± 6.38
#
Oc.N/10 HPF 5 ± 1.41 17 ± 2.40 * 16 ± 2.39 17 ± 2.20 13 ± 2.26 10 ± 1.41
#
Note: Results are presented as the means ± SD. *p < 0.001 vs. Sham group;
#p < 0.05 vs. OVX group. BV/TV, bone volume fraction; Tb.Th, trabecular thickness; Tb.
N, trabecular number; Tb.Sp, trabecular separation; Oc.N, osteoclast number. Rat groups as defined above (N = 7/each group).
Figure 2 The image analysis of rat medial-proximal tibia in SM-treated rats. A, Coronal images of rat medial-proximal tibia were shown by
μ-CT. B, 3D images taken by μ-CT.
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increased serum MDA levels (p < 0.001 vs. Sham rats),
meaning the induction of lipid peroxydation in OVX
rats (Figure 5C). SM treatment, especially at the two
groups, 10 and 30SM, significantly attenuated the MDA
increase induced by OVX (p <0 . 0 0 1a n dp <0 . 0 1 ,
respectively). Figure 5D showed that OVX significantly
increased total serum nitrate, metabolite of NO (p <
0.001 vs. Sham rats), and in 10SM and 30SM rats, SM
treatment significantly prevented the nitrate increase
induced by OVX (p < 0.001 vs. Sham rats).
Serum Biochemical Levels
Serum calcitonin and intact PTH levels were not signifi-
cantly different among experimental groups (data not
shown). As shown in Table 4, serum calcium and IP
levels and free T3 were not significantly different among
experimental groups, while OVX significantly decreased
estradiol (p < 0.01) but the SM did not affect the
decrease of estradiol. Free T4 was significantly increased
in OVX rats (p < 0.001) and the increase was signifi-
cantly attenuated in 30SM rats (p < 0.001). OVX signifi-
cantly increased serum osteocalcin and ALP activity (p
< 0.001 and 0.05, respectively) and SM treatment did
not affect the increase.
Discussion
OVX induced significant trabecular bone loss due to
estrogen deficiency and subsequent increased bone turn-
over. SM at 30 mg/kg body weight/day dosage signifi-
cantly attenuated trabecular bone loss and BMD
decrease induced by OVX. SM can contribute to bone
balance probably through preventing an increase in
osteoclast number by decreasing osteoclast maturation.
SM is a potential anti-osteoporotic natural product.
For several decades, SM has been widely used for the
treatment of various microcirculatory disturbance-
related diseases, such as cardiovascular disease, cerebro-
vascular disease, liver dysfunction, renal deficiency and
diabetic vascular complications [4]. SM extract is also
reported to increase bone formation through the com-
bined actions of increased angiogenesis, increased osteo-
blastic activity and decreased osteoclastic activity [10].
In the current study, treatment with 30 mg/kg of etha-
nol extracts of SM significantly attenuated the dramatic
decrease in BMD and deterioration in trabecular bone
architecture (Table 1 &2).
SM treatment also significantly prevented increases in
serum nitrate and peroxide levels and ameliorated the
increase in mononuclear cellular infiltration in the por-
tal area of the liver (Table 3). In the current study, his-
tological examination of the liver of the SM treated rats
showed the regulatory effect of mononuclear cellular
infiltration (Figure 4). Previous studies have showed that
OVX condition induces liver inflammation [24,25]. The
estrogen-induced prevention effect against bone loss
may involve suppression of inflammatory cytokines such
as IL 1, IL-6 or TNF-a, which in turn activate inducible
nitric oxide synthase (iNOS). Nitric oxide (NO) is
derived from the iNOS pathway potentiates the
Figure 3 Bone histochemical section images of proximal
metaphysis of tibia. A, Sham group: trabecular bone (T) and bone
marrow spaces (M). B, OVX group: significantly increased bone
marrow space, decreased trabecular network. C, 30 mg/kg of SM
treatment significantly attenuated trabecular network loss compared
with Sham rats. (H & E, ×100).
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studies give a possible explanation for the detected sig-
nificant increase in the plasma nitrates level present in
the OVX-rats in our study. Malondialdehyde (MDA)
was also significantly increased in the OVX rats indicat-
ing increased oxidative stress. In the current study, SM
treatment regulated the production of NO and MDA,
which are related with bone resorption. It has been
demonstrated that free radicals intervene in bone
resorption, promoting osteoclastic differentiation [26].
Considering that enhanced osteoclastic activity in OVX
rats has been suggested to be responsible for increased
ROS [27], the regulatory effect of SM on NO and MDA
could be one of the anti-osteoporotic mechanisms of
the natural product.
In this study, SM treatment also significantly attenu-
ated the increase in bone osteoclast number and serum
TRAP-5b but did not affect the increase in serum BALP
and ALP or in osteocalcin and estradiol induced by
OVX. Generally, in subjects with normal liver function,
serum ALP is similar to BALP and reflects osteoblast
function [28]. Together with osteocalcin, they are mar-
kers of bone formation, while TRAP-5b is a bone
resorption marker [22]. In the serum biochemical
assessment, OVX did not affect serum calcium and IP
levels or PTH and calcitonin activity, but significantly
increased free T4 activity compared with Sham rats
(Table 4). Free T4 activity was significantly reduced in
30SM rats compared with OVX rats (also shown in
Table 4). Thyroid hormones play an important role in
bone remodeling [29]. Histomorphometric studies have
shown that thyroid hormones stimulate osteoblastic and
osteoclastic activities in cortical and trabecular bone
[30]. Thyrotoxicosis is associated with increased bone
turnover, which can lead to a resorption rate that
exceeds the formation rate, thus resulting in bone loss
[31]. Considering that an increased rate of bone turn-
over was observed in subjects loaded with suppressive
doses of T4, the inhibition of the increase of T4 levels by
SM further suggests that SM has a regulatory effect on
bone turnover. Increases in bone turnover have been
reported in the perimenopausal period in humans prob-
ably due to estrogen deficiency [32]. Consistently, estra-
diol decrease was observed in OVX rats (Table 4). The
reduced estradiol was not recovered by SM treatment.
But with the data about estrogen, we could not
Table 3 The number of infiltrated mononuclear cells in the portal area of liver/10 HPF (×200).
Parameters Sham
n=7
OVX
n=7
1SM
n=7
3SM
n=7
10SM
n=7
30SM
n=7
Infiltrated Mononuclear cellular NO/10 HPF 1.57 ± 1.27 12.00 ± 2.40 * 12.00 ± 2.39 11.50 ± 2.20 10.38 ± 2.26 8.50 ± 2.34
#
Note: Results are presented as the means ± SD. *p < 0.001 vs. Sham group;
#p < 0.05 vs. OVX group. Rat groups as defined above (N = 7/each group).
Figure 4 Liver histochemical section images. Plates of liver parenchymal cells and sinusoids among the laminae of hepatic cells radiating
from the central vein (®) and radiating towards the portal area (®). Upper (H & E, ×100) and Lower (H & E, ×200).
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Parameters Sham
n=1 0
OVX
n=1 0
SM1
n=7
SM3
n=8
SM10
n=1 0
SM30
n=9
ALP (U/L) 32.57 ± 8.28 51.29 ± 7.78
& 47.71 ± 5.38 51.57 ± 3.74 51.14 ± 8.80 47.57 ± 7.00
Estradiol (pg/mL) 16.09 ± 3.38 9.29 ± 2.51
# 10.27 ± 3.18 8.10 ± 3.03 9.07 ± 2.60 10.10 ± 3.23
Free T3 (pg/mL) 3.84 ± 0.50 3.83 ± 0.31 3.97 ± 0.31 3.91 ± 0.23 3.79 ± 0.41 3.74 ± 0.23
Free T4 (ng/dL) 1.90 ± 0.47 3.04 ± 0.25 * 3.07 ± 0.30 2.89 ± 0.31 2.73 ± 0.23 2.00 ± 0.51
%
Osteocalcin (ng/mL) 2.40 ± 0.28 3.66 ± 0.48 * 3.40 ± 0.57 3.63 ± 0.44 3.44 ± 0.43 3.47 ± 0.42
Calcium (mg/dL) 9.30 ± 0.41 9.46 ± 0.29 9.63 ± 0.21 9.78 ± 0.46 9.40 ± 0.27 9.70 ± 0.51
IP (mg/dL) 6.21 ± 0.80 6.24 ± 0.65 6.60 ± 0.57 6.50 ± 0.72 6.17 ± 0.53 6.49 ± 0.79
Note: T3, triiodothyronine; T4, thyroxine, IP, inorganic phosphorus. Results are presented as the means ± SD. *p < 0.001 vs. Sham group;
#p< 0.01 vs. Sham group;
&p < 0.05 vs. Sham group;
%p < 0.001 vs. OVX group. Rat groups as defined above (N = 6/each group).
Figure 5 Serum bone turnover marker levels. Serum BALP activity (A), seru m TRAP-5b activity (B), Serum MDA levels (C) and serum nitrate
levels (D) were measured as described in Materials and Methods. Note: (A) to (B) *p < 0.05 vs Sham rats;
#p < 0.05 vs OVX rats. (C) *p < 0.001 vs
Sham group;
#p < 0.001 vs OVX group. (D) *p < 0.001 vs Sham rats;
#p < 0.001 vs OVX rats;
&p < 0.01 vs OVX rats.
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Although we did not clarify the characteristics of SM
about hormone-like effect, we are suggesting that SM
prevents trabecular bone loss by modulating osteoclast
activity including decreasing osteoclast number/by
decreasing osteoclast maturation, resulting in the regula-
tion of bone turnover rate rather than by deceasing
estrogen level.
The pharmacokinetics studies of these active compo-
nents of SM in animals showed that they are absorbed
orally and randomized clinical trials and clinical experi-
ences indicate that the SM products are safe with a low
side-effect profile [5]. Therefore, SM is a promising
osteoporosis therapeutic agent candidate, although the
specific mechanism of the anti-osteoporotic effect of SM
needs to be clarified.
Conclusions
The preventive effect of SM against osteoporosis was
presumably due to its anti-oxidative stress partly via
modulation of osteoclast maturation and number. In
current study, SM has been suggested to be a promising
osteoporosis therapeutic natural product.
Additional material
Additional file 1: Chromatogram of constituents from SM extracts
by HPLC analysis. The chromatogram shows peaks about Tanshinone
IIA and cryptotanshinone. The retention time for cryptotanshinone and
tanshinone IIA was 14.8 and 21.6 min. The content of tanshinone IIA and
cryptotanshinone in Salvia Miltiorrhiza was 106.56 μg/10 mg (1.07%) and
109.655 μg/10 mg (1.10%).
Additional file 2: HPLC analysis methods for measurement of the
standards of Tanshinone IIA and Cryptotanshinone. The Additional
file shows HPLC analysis method for the standard chemicals “Tanshinone
IIA and Cryptotanshinone”.
Additional file 3: Changes in body weight growth in rats. The
additional file shows the rat’s body weights from the second week after
OVX (including OVX and all drug administration groups).
Additional file 4: Coronal image of proximal-medial tibia taken ex
vivo by μ-CT. The additional file shows conditions for μ-CT (references
Set distal growth plate as reference level and 8 mm distal from distal
growth plate as cortical area analysis cut level and the related transaxial
image of tibial diaphysis).
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thyroxine; Tb.N: trabecular number; Tb.Pf: trabecular bone pattern factor; Tb.
Sp: trabecular separation; Tb.Th: trabecular thickness; TNF-α: tumor necrosis
factor α; TRAP: tartrate-resistant acid phosphatase; TRAP-5b: type 5 tartrate
resistant acid phosphatase band
Acknowledgements
This work was supported by the National Research Foundation Grants (2010-
0029477, 2009-0087202) and was partly supported by Korea Research
Foundation (KRF-2008-313-E00540) and by Korea Science and Engineering
Foundation Grants (R01-2007-000-20275-0). We appreciate YJ Chang for
technical assistance about μ-CT (Basic Research Institute, Jeonju, Korea).
Author details
1Department of Pharmacology and Institute of Cardiovascular Research,
School of Medicine, Chonbuk National University, Jeonju, Chonbuk, South
Korea.
2Department of Dental Pharmacology and Wonkwang Dental
Research Institute, School of Dentistry, Wonkwang University, Iksan, Chonbuk,
South Korea.
Authors’ contributions
YC mainly performed the animal experiment, analyzed the data and wrote a
draft. AM did quantitative analysis of danshen. SC partially wrote a draft. BB,
GL, BL and DK supported the animal experiment, especially for feeding and
establishing osteoporosis model. HK and HC supervised the project and
wrote the final paper. All authors read and approved the final manuscript.
Competing interests
We declare that we have no competing interests. We also declare that we
have no financial and non-financial competing interests.
Received: 24 July 2011 Accepted: 28 November 2011
Published: 28 November 2011
References
1. Anon.: Osteoporosis prevention, diagnosis, and therapy. Jama 2001,
285:785-795.
2. Vassilopoulou-Sellin R: Breast cancer and hormonal replacement therapy.
Ann N Y Acad Sci 2003, 997:341-350.
3. Wang X, Morris-Natschke SL, Lee KH: New developments in the chemistry
and biology of the bioactive constituents of Tanshen. Med Res Rev 2007,
27:133-148.
4. Han JY, Fan JY, Horie Y, Miura S, Cui DH, Ishii H, Hibi T, Tsuneki H, Kimura I:
Ameliorating effects of compounds derived from Salvia miltiorrhiza root
extract on microcirculatory disturbance and target organ injury by
ischemia and reperfusion. Pharmacol Ther 2008, 117:280-295.
5. Zhou L, Zuo Z, Chow MS: Danshen: an overview of its chemistry,
pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 2005,
45:1345-1359.
6. Zhu YZ, Huang SH, Tan BK, Sun J, Whiteman M, Zhu YC: Antioxidants in
Chinese herbal medicines: a biochemical perspective. Nat Prod Rep 2004,
21:478-489.
7. Kim HH, Kim JH, Kwak HB, Huang H, Han SH, Ha H, Lee SW, Woo ER,
Lee ZH: Inhibition of osteoclast differentiation and bone resorption by
tanshinone IIA isolated from Salvia miltiorrhiza Bunge. Biochem
Pharmacol 2004, 67:1647-1656.
8. Zhang Y, Akao T, Nakamura N, Duan CL, Hattori M, Yang XW, Liu JX:
Extremely low bioavailability of magnesium lithospermate B, an active
component from Salvia miltiorrhiza in rat. Planta Med 2004, 70:138-142.
9. Lay IS, Chiu JH, Shiao MS, Lui WY, Wu CW: Crude extract of Salvia
miltiorrhiza and salvianolic acid B enhance in vitro angiogenesis in
murine SVR endothelial cell line. Planta Med 2003, 69:26-32.
10. Wong RW, Rabie AB: Effect of Salvia miltiorrhiza extract on bone
formation. J Biomed Mater Res A 2008, 85:506-512.
11. Ding Y, Soma S, Takano-Yamamoto T, Matsumoto S, Sakuda M: Effects of
salvia miltiorrhiza bunge (SMB) on MC3T3-E1 cells. J Osaka Univ Dent Sch
1995, 35:21-27.
12. Chae HJ, Chae SW, Yun DH, Keum KS, Yoo SK, Kim HR: Prevention of bone
loss in ovariectomized rats: the effect of Salvia miltiorrhiza extracts.
Immunopharmacol Immunotoxicol 2004, 26:135-144.
13. Brouwers JE, Lambers FM, Gasser JA, van Rietbergen B, Huiskes R: Bone
degeneration and recovery after early and late bisphosphonate
treatment of ovariectomized wistar rats assessed by in vivo micro-
computed tomography. Calcif Tissue Int 2008, 82:202-211.
Cui et al. BMC Complementary and Alternative Medicine 2011, 11:120
http://www.biomedcentral.com/1472-6882/11/120
Page 10 of 1114. Jiang SD, Shen C, Jiang LS, Dai LY: Differences of bone mass and bone
structure in osteopenic rat models caused by spinal cord injury and
ovariectomy. Osteoporos Int 2007, 18:743-750.
15. Kim DS, Han SH, Lee YC, Park SJ, Yoo WH, Kim HR, Chae HJ: The study of
the combination of Slavia Miltiorrhiza and Kitosan on osteoporosis in
ovariectomized rats. Kor J Clin Pharm 2009, 19(2):75-80.
16. Jarvinen TL, Sievanen H, Kannus P, Jarvinen M: Dual-energy X-ray
absorptiometry in predicting mechanical characteristics of rat femur.
Bone 1998, 22:551-558.
17. Gothe S, Wang Z, Ng L, Kindblom JM, Barros AC, Ohlsson C, Vennström B,
Forrest D: Mice devoid of all known thyroid hormone receptors are
viable but exhibit disorders of the pituitary-thyroid axis, growth, and
bone maturation. Genes Dev 1999, 13:1329-1341.
18. Kannus P, Jarvinen TL, Sievanen H, Kvist M, Rauhaniemi J, Maunu VM,
Hurme T, Jozsa L, Järvinen M: Effects of immobilization, three forms of
remobilization, and subsequent deconditioning on bone mineral
content and density in rat femora. J Bone Miner Res 1996, 11:1339-1346.
19. Kastl S, Sommer T, Klein P, Hohenberger W, Engelke K: Accuracy and
precision of bone mineral density and bone mineral content in excised
rat humeri using fan beam dual-energy X-ray absorptiometry. Bone 2002,
30:243-246.
20. Draper HH, Hadley M: Malondialdehyde determination as index of lipid
peroxidation. Methods Enzymol 1990, 186:421-431.
21. Bories PN, Bories C: Nitrate determination in biological fluids by an
enzymatic one-step assay with nitrate reductase. Clin Chem 1995,
41:904-907.
22. Cremers S, Garnero P: Biochemical markers of bone turnover in the
clinical development of drugs for osteoporosis and metastatic bone
disease: potential uses and pitfalls. Drugs 2006, 66:2031-2058.
23. Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM, Vaananen HK: Tartrate-
resistant acid phosphatase 5b (TRACP 5b) as a marker of bone
resorption. Clin Lab 2006, 52:499-509.
24. Kireev RA, Tresguerres AC, Garcia C, Borras C, Ariznavarreta C, Vara E, Vina J,
Tresguerres JA: Hormonal regulation of pro-inflammatory and lipid
peroxidation processes in liver of old ovariectomized female rats.
Biogerontology 2010, 11:229-243.
25. Van’t Hof RJ, Ralston SH: Nitric oxide and bone. Immunology 2001, 103:255 261.
26. Sánchez-Rodríguez MA, Ruiz-Ramos M, Correa-Muñoz E, Mendoza-
Núñez VM: Oxidative stress as a risk factor for osteoporosis in elderly
Mexicans as characterized by antioxidant enzymes. BMC Musculoskelet
Disord 2007, 19(8):124.
27. Koh JM, Lee YS, Kim YS, Kim DJ, Kim HH, Park JY, Lee KU, Kim GS:
Homocysteine enhances bone resorption by stimulation of osteoclast
formation and activity through increased intracellular ROS generation.
J Bone Miner Res 2006, 21(7):1003-11.
28. Farley JR, Chesnut CH, Baylink DJ: Improved method for quantitative
determination in serum of alkaline phosphatase of skeletal origin. Clin
Chem 1981, 27:2002-2007.
29. Mosekilde L, Eriksen EF, Charles P: Effects of thyroid hormones on bone
and mineral metabolism. Endocrinol Metab Clin North Am 1990, 19:35-63.
30. Mosekilde L, Melsen F, Bagger JP, Myhre-Jensen O, Schwartz Sorensen N:
Bone changes in hyperthyroidism: interrelationships between bone
morphometry, thyroid function and calcium-phosphorus metabolism.
Acta Endocrinol (Copenh) 1977, 85:515-525.
31. Madsen JE, Aune AK, Falch JA, Hukkanen M, Konttinen YT, Santavirta S,
Nordsletten L: Neural involvement in post-traumatic osteopenia: an
experimental study in the rat. Bone 1996, 18:411-416.
32. Nilas L, Christiansen C: Rates of bone loss in normal women: evidence of
accelerated trabecular bone loss after the menopause. Eur J Clin Invest
1988, 18:529-534.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1472-6882/11/120/prepub
doi:10.1186/1472-6882-11-120
Cite this article as: Cui et al.: Characterization of Salvia Miltiorrhiza
ethanol extract as an anti-osteoporotic agent. BMC Complementary and
Alternative Medicine 2011 11:120.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Cui et al. BMC Complementary and Alternative Medicine 2011, 11:120
http://www.biomedcentral.com/1472-6882/11/120
Page 11 of 11